if it is pfizer

something i've been thinking since the little hint that pfizer doing the DD (now negotiation):
Do you think there is any chance that Pfizer would lock this up to protect its Somavert market?
Apparently this could make Somavert more effective, so i see how the potential for extra bucks on the same patient would be attractive to Pfizer.
But if this has the potential to decrease the profits they would make, is there any chance we could be locking away a cracker of a compound to never see the light of production?

Judging by those more in the know than I, management of ANP is top notch, so i'm confident that any agreement would cover this possibility.

Was just my thoughts, dont even think its likely.